Mr. DeSeabra has also established manufacturing, quality and compliance programs with companies including Tunnell Consulting and Kyamanox. He was recruited by TiGenix to establish manufacturing and quality operations for an autologous cell therapy-based product. Prior to that, he led development, documentation and commercialization efforts for OxThera.
“We are pleased to welcome Alex to IPS,” said Dave Goswami, PE, chief executive officer and chairman, IPS. “He brings a broad range of global biopharmaceutical experience, including cutting-edge technical expertise and extensive international compliance knowledge to help our multi-national clients maximize their growth potential. With our growing international business and our new focus on Latin Americas, Alex fulfills a key role in our growth. With the addition of Alex, IPS is well-positioned to achieve our clients’ strategic goals and business objectives in Brazil and other countries within Latin America.”